lapatinib / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

206 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
2009-009928-37: Phase 1/2 Studie:CONKO-008Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie

Ongoing
1/2
95
Europe
Lapatinib, GW572016, Tyverb, MEDOXA, Fluorouracil-GRY, Calciumfolinat-GRY, Tyverb, MEDOXA, Fluorouracil-GRY, Calciumfolinat-GRY
Charite Universitätsmedizin Berlin
Pancreatic cancer patients who failed first line therapy with gemcitabine
 
 
2011-002167-23: A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic breast cancer. Etude de phase Ib/II évaluant la sécurité et l’efficacité du BKM120 en combinaison avec le lapatinib dans les cancers du sein récidivants, localement avancés ou métastatiques, HER2+ résistants au trastuzumab avec activation de la voie PI3K

Ongoing
1/2
59
Europe
BKM 120, TYVERB, TYVERB
Institut Paoli-Calmettes, Programme Hospitalier de Recherche Clinique (PHRC), Laboratoires Novartis
locally advanced, recurrent and metastatic breast cancer.
 
 
NCT02422199: A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Unknown status
1/2
128
RoW
pyrotinib, Lapatinib, capecitabine
Jiangsu HengRui Medicine Co., Ltd.
HER2 Positive Metastatic Breast Cancer
10/16
12/18
PIKHER2, NCT01589861: Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Suspended
1/2
106
Europe
BKM120 + lapatinib, BKM120 and lapatinib
Institut Paoli-Calmettes
Breast Cancer
01/18
01/18
M14LTK, NCT02230553: Lapatinib Plus Trametinib in KRAS Mutant NSCLC

Unknown status
1/2
30
Europe
Lapatinib, trametinib
The Netherlands Cancer Institute, GlaxoSmithKline
Colorectal Cancer
08/18
12/19
2019-004987-23: RASTRIC-trial: investigating the safety and efficacy of a new three drug treatment combination for RAS-mutated metastastic colorectal cancer. RASTRIC-studie: onderzoek naar de veiligheid en effectiviteit van een nieuwe behandeling met drie middelen voor RAS-gemuteerde uitgezaaide dikke darmkanker.

Not yet recruiting
1/2
50
Europe
Mektovi, Tyverb, vinorelbine, EMEA/H/C/004579, EMEA/H/C/000795, RVG 35294, Film-coated tablet, Concentrate and solvent for solution for infusion, Mektovi, Tyverb, vinorelbine
UMC Utrecht, ONCODE institute, UMC Utrecht
colorectal cancer colorectaal carcinoom, colorectal cancer dikkedarmkanker, Diseases [C] - Cancer [C04]
 
 
 

Download Options